bioAffinity Technologies, Inc.
BIAFNasdaqIndustrials · Services-Commercial Physical & Biological Research · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $2.5M | $4,803 | — |
| Operating income | −$10.6M | −$9.0M | −$8.0M | −$4.0M | −$2.2M |
| Net income | −$14.9M | −$9.0M | −$7.9M | −$8.2M | −$6.3M |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M |
| Equity | $7.3M | $2.6M | $4.9M | $11.0M | −$15.8M |
| EPS (diluted) | $-8.66 | $-0.75 | $-0.91 | $-1.81 | $-2.36 |
| Shares out. | 18.3M | 11.5M | 8.5M | 8.4M | 2.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −171.6%
- Net margin
- −242.0%
- Return on equity
- −204.9%
- Return on assets
- −136.0%
- Return on capital (ROCE)
- −131.3%
- Liabilities / assets
- 33.6%
- Debt / equity
- 0.51×
- Book value / share
- $0.40
- Revenue growth (YoY)
- −34.2%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -22.01distress
- Accruals / assets
- −50.9%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bigger Capital Fund L PPassive (13G)Oct 1, 2025
- Crumly Richard K.Passive (13G)May 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Reveles Xavier TrinidadOfficer — Chief Operating Officer | Jan 10, 2025 | Grant | 21,604 | $0.00 |
| Girgenti StevenOfficer — Executive Chairman | Jan 10, 2025 | Grant | 14,814 | $0.00 |
| Zannes MariaOfficer — President & CEO | Jan 10, 2025 | Grant | 37,037 | $0.00 |
| Edwards James MichaelOfficer — VP and CFO | Jan 10, 2025 | Grant | 6,172 | $0.00 |
| Zannes Timothy POfficer — Secretary, EVP, Gen. Counsel | Jan 10, 2025 | Grant | 8,641 | $0.00 |
| Edwards James MichaelOfficer — VP and CFO | Nov 5, 2024 | Grant | 100,000 | $0.00 |
| Diamond StuartDirector | Jul 1, 2024 | Grant | 33,784 | $0.00 |
| Girgenti StevenOfficer — Executive Chairman | Jul 1, 2024 | Grant | 33,784 | $0.00 |
| Anderson Robert A.Director | Jul 1, 2024 | Grant | 33,784 | $0.00 |
| Joyce RobyDirector | Jul 1, 2024 | Grant | 33,784 | $0.00 |
| Zannes MariaOfficer — President & CEO | Jul 1, 2024 | Grant | 33,784 | $0.00 |
| Platt JamieDirector | Jul 1, 2024 | Grant | 33,784 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 494,011 | 1.9 | -27.0% |
| Apr 30, 2026 | 676,404 | 1.4 | +31.1% |
| Apr 15, 2026 | 515,756 | 1.0 | -4.9% |
| Mar 31, 2026 | 542,083 | 1.0 | +1.2% |
| Mar 13, 2026 | 535,630 | 1.0 | +142.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventMay 27, 2026
- Other material eventMay 12, 2026
- Results of operationsMay 8, 2026
- Director / officer change · Shareholder voteApr 30, 2026
- Other material eventApr 14, 2026
- Other material eventApr 7, 2026
- Other material eventApr 1, 2026
- Regulation FD disclosureMar 26, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.